RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPAC

Rare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund a rare genetic disease candidate.